Nissay Asset Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.54M | Sell |
12,250
-43
| -0.3% | -$5.41K | 0.01% | 556 |
|
|
2025
Q1 | $1.36M | Buy |
12,293
+107
| +0.9% | +$11.8K | 0.01% | 582 |
|
|
2024
Q4 | $1.7M | Buy |
12,186
+146
| +1% | +$20.4K | 0.01% | 560 |
|
|
2024
Q3 | $1.39M | Buy |
12,040
+466
| +4% | +$53.7K | 0.01% | 598 |
|
|
2024
Q2 | $1.59M | Buy |
11,574
+401
| +4% | +$55.2K | 0.01% | 553 |
|
|
2024
Q1 | $1.54M | Buy |
11,173
+233
| +2% | +$32.1K | 0.01% | 563 |
|
|
2023
Q4 | $1.44M | Buy |
10,940
+354
| +3% | +$46.6K | 0.01% | 549 |
|
|
2023
Q3 | $1.19M | Buy |
10,586
+354
| +3% | +$39.8K | 0.01% | 569 |
|
|
2023
Q2 | $965K | Sell |
10,232
-191
| -2% | -$18K | 0.01% | 615 |
|
|
2023
Q1 | $1.06M | Sell |
10,423
-402
| -4% | -$40.7K | 0.01% | 595 |
|
|
2022
Q4 | $1.29M | Sell |
10,825
-237
| -2% | -$28.3K | 0.01% | 538 |
|
|
2022
Q3 | $1.18M | Buy |
11,062
+431
| +4% | +$45.8K | 0.01% | 549 |
|
|
2022
Q2 | $1.04M | Sell |
10,631
-130
| -1% | -$12.7K | 0.01% | 578 |
|
|
2022
Q1 | $1.01M | Buy |
10,761
+265
| +3% | +$24.8K | 0.01% | 609 |
|
|
2021
Q4 | $894K | Buy |
10,496
+419
| +4% | +$35.7K | 0.01% | 663 |
|
|
2021
Q3 | $966K | Buy |
10,077
+409
| +4% | +$39.2K | 0.01% | 627 |
|
|
2021
Q2 | $941K | Buy |
9,668
+440
| +5% | +$42.8K | 0.01% | 644 |
|
|
2021
Q1 | $897K | Sell |
9,228
-222
| -2% | -$21.6K | 0.01% | 628 |
|
|
2020
Q4 | $906K | Buy |
9,450
+358
| +4% | +$34.3K | 0.01% | 608 |
|
|
2020
Q3 | $874K | Buy |
9,092
+237
| +3% | +$22.8K | 0.01% | 573 |
|
|
2020
Q2 | $1.08M | Buy |
8,855
+1,159
| +15% | +$141K | 0.02% | 499 |
|
|
2020
Q1 | $666K | Buy |
7,696
+318
| +4% | +$27.5K | 0.02% | 525 |
|
|
2019
Q4 | $793K | Buy |
+7,378
| New | +$793K | 0.02% | 587 |
|